Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine

Daria H. Pardridge, F. C. Sparks, James E Goodnight Jr, Irene K. Spears, D. L. Morton

Research output: Contribution to journalArticle

Abstract

Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.

Original languageEnglish (US)
Pages (from-to)217-220
Number of pages4
JournalCancer Immunology and Immunotherapy
Volume5
Issue number4
DOIs
StatePublished - Feb 1979

Fingerprint

Cancer Vaccines
Mycobacterium bovis
Breast Neoplasms
Drug Therapy
Neoplasms
Neoplasm Micrometastasis
Mastectomy
Alopecia
Pruritus
Adjuvant Chemotherapy
Growth
Hepatitis B
Serum
Hepatitis B virus
Nausea
Vomiting
Fatigue
Fever
Injections
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine. / Pardridge, Daria H.; Sparks, F. C.; Goodnight Jr, James E; Spears, Irene K.; Morton, D. L.

In: Cancer Immunology and Immunotherapy, Vol. 5, No. 4, 02.1979, p. 217-220.

Research output: Contribution to journalArticle

Pardridge, Daria H. ; Sparks, F. C. ; Goodnight Jr, James E ; Spears, Irene K. ; Morton, D. L. / Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine. In: Cancer Immunology and Immunotherapy. 1979 ; Vol. 5, No. 4. pp. 217-220.
@article{b5ebb901f3d444de91dc75ee8243907c,
title = "Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine",
abstract = "Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.",
author = "Pardridge, {Daria H.} and Sparks, {F. C.} and {Goodnight Jr}, {James E} and Spears, {Irene K.} and Morton, {D. L.}",
year = "1979",
month = "2",
doi = "10.1007/BF00200143",
language = "English (US)",
volume = "5",
pages = "217--220",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Chemoimmunotherapy of stage III breast carcinoma with BCG and a live allogeneic tumor cell vaccine

AU - Pardridge, Daria H.

AU - Sparks, F. C.

AU - Goodnight Jr, James E

AU - Spears, Irene K.

AU - Morton, D. L.

PY - 1979/2

Y1 - 1979/2

N2 - Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.

AB - Ten women with metastatic breast carcinoma were treated with CMF, BCG, and a live TCV in a phase I study to determine whether viable allogeneic tumor cells can safely be given to women receiving adjuvant chemotherapy. Side effects of fatigue, nausea, vomiting, alopecia, and myelosuppression were attributable to chemotherapy. Side effects of BCG therapy were malaise, fever, and pruritis at the injection site, as previously described. Four patients developed hepatitis B due to viral contamination of the human agamma serum in which the tumor cells were grown. This complication has now been eliminated by omitting human sera, and hence the possibility of hepatitis B virus, from tumor cell growth media. No local tumor growth was observed in any patient. Results of this study show that live TCV is safe for patients receiving chemotherapy, and could be tested in combination with BCG and chemotherapy for control of micrometastases from breast cancer following mastectomy.

UR - http://www.scopus.com/inward/record.url?scp=0018648017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018648017&partnerID=8YFLogxK

U2 - 10.1007/BF00200143

DO - 10.1007/BF00200143

M3 - Article

AN - SCOPUS:0018648017

VL - 5

SP - 217

EP - 220

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 4

ER -